Search

Your search keyword '"Martin, Elizabeth E."' showing total 13 results
Start Over Author "Martin, Elizabeth E."
13 results on '"Martin, Elizabeth E."'

1. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations

Author

Varkaris, Andreas, primary, Fece de la Cruz, Ferran, additional, Martin, Elizabeth E., additional, Norden, Bryanna L., additional, Chevalier, Nicholas, additional, Kehlmann, Allison M., additional, Leshchiner, Ignaty, additional, Barnes, Haley, additional, Ehnstrom, Sara, additional, Stavridi, Anastasia-Maria, additional, Yuan, Xin, additional, Kim, Janice S., additional, Ellis, Haley, additional, Papatheodoridi, Alkistis, additional, Gunaydin, Hakan, additional, Danysh, Brian P., additional, Parida, Laxmi, additional, Sanidas, Ioannis, additional, Ji, Yongli, additional, Lau, Kayao, additional, Wulf, Gerburg M., additional, Bardia, Aditya, additional, Spring, Laura M., additional, Isakoff, Steven J., additional, Lennerz, Jochen K., additional, Del Vecchio, Kathryn, additional, Pierce, Levi, additional, Pazolli, Ermira, additional, Getz, Gad, additional, Corcoran, Ryan B., additional, and Juric, Dejan, additional

Published
2023
Full Text
View/download PDF

2. Data from Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Author

Coates, James T., primary, Sun, Sheng, primary, Leshchiner, Ignaty, primary, Thimmiah, Nayana, primary, Martin, Elizabeth E., primary, McLoughlin, Daniel, primary, Danysh, Brian P., primary, Slowik, Kara, primary, Jacobs, Raquel A., primary, Rhrissorrakrai, Kahn, primary, Utro, Filippo, primary, Levovitz, Chaya, primary, Denault, Elyssa, primary, Walmsley, Charlotte S., primary, Kambadakone, Avinash, primary, Stone, James R., primary, Isakoff, Steven J., primary, Parida, Laxmi, primary, Juric, Dejan, primary, Getz, Gad, primary, Bardia, Aditya, primary, and Ellisen, Leif W., primary

Published
2023
Full Text
View/download PDF

3. Supplementary Figures S1-S4; Supplementary Tables S1-S4 from Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Author

Coates, James T., primary, Sun, Sheng, primary, Leshchiner, Ignaty, primary, Thimmiah, Nayana, primary, Martin, Elizabeth E., primary, McLoughlin, Daniel, primary, Danysh, Brian P., primary, Slowik, Kara, primary, Jacobs, Raquel A., primary, Rhrissorrakrai, Kahn, primary, Utro, Filippo, primary, Levovitz, Chaya, primary, Denault, Elyssa, primary, Walmsley, Charlotte S., primary, Kambadakone, Avinash, primary, Stone, James R., primary, Isakoff, Steven J., primary, Parida, Laxmi, primary, Juric, Dejan, primary, Getz, Gad, primary, Bardia, Aditya, primary, and Ellisen, Leif W., primary

Published
2023
Full Text
View/download PDF

5. Author Correction: Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Author

Parikh, Aparna R., Leshchiner, Ignaty, Elagina, Liudmila, Goyal, Lipika, Levovitz, Chaya, Siravegna, Giulia, Livitz, Dimitri, Rhrissorrakrai, Kahn, Martin, Elizabeth E., Van Seventer, Emily E., Hanna, Megan, Slowik, Kara, Utro, Filippo, Pinto, Christopher J., Wong, Alicia, Danysh, Brian P., de la Cruz, Ferran Fece, Fetter, Isobel J., Nadres, Brandon, Shahzade, Heather A., Allen, Jill N., Blaszkowsky, Lawrence S., Clark, Jeffrey W., Giantonio, Bruce, Murphy, Janet E., Nipp, Ryan D., Roeland, Eric, Ryan, David P., Weekes, Colin D., Kwak, Eunice L., Faris, Jason E., Wo, Jennifer Y., Aguet, François, Dey-Guha, Ipsita, Hazar-Rethinam, Mehlika, Dias-Santagata, Dora, Ting, David T., Zhu, Andrew X., Hong, Theodore S., Golub, Todd R., Iafrate, A. John, Adalsteinsson, Viktor A., Bardelli, Alberto, Parida, Laxmi, Juric, Dejan, Getz, Gad, and Corcoran, Ryan B.

Published
2019
Full Text
View/download PDF

6. Abstract 5162: TuFEst: a sensitive and cost-effective pan-cancer detection approach with accurate tumor fraction estimation

Author

Lin, Ziao, primary, Stewart, Chip, additional, Martin, Elizabeth E., additional, Danysh, Brian P., additional, Jacobs, Raquel A., additional, Slowik, Kara, additional, Lawton, Lee, additional, Lightbody, Elizabeth, additional, Rhrissorrakrai, Kahn, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Cibulskis, Carrie, additional, Ghobrial, Irene M., additional, Shipp, Margaret, additional, Corcoran, Ryan B., additional, Juric, Dejan, additional, Parida, Laxmi, additional, Parsons, Heather A., additional, and Getz, Gad, additional

Published
2022
Full Text
View/download PDF

7. Abstract 1789: Chromatin modifier alterations confer resistance to endocrine deprivation and CDK4/6 inhibitors in ER+ breast cancer and drive convergent evolution in patient autopsy lesions

Author

Leshchiner, Elizaveta, primary, Leshchiner, Ignaty, additional, Martin, Elizabeth E., additional, Chen, Christopher T., additional, Zhang, Thomas, additional, Pinto, Christopher, additional, Rhrissorrakrai, Kahn, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Jacobs, Raquel A., additional, Danysh, Brian P., additional, Slowik, Kara, additional, Broudo, Maida, additional, Parida, Laxmi, additional, Juric, Dejan, additional, and Getz, Gad, additional

Published
2022
Full Text
View/download PDF

8. Parallel Genomic Alterations of Antigen and Payload Targets Mediate Polyclonal Acquired Clinical Resistance to Sacituzumab Govitecan in Triple-Negative Breast Cancer

Author

Coates, James T., primary, Sun, Sheng, additional, Leshchiner, Ignaty, additional, Thimmiah, Nayana, additional, Martin, Elizabeth E., additional, McLoughlin, Daniel, additional, Danysh, Brian P., additional, Slowik, Kara, additional, Jacobs, Raquel A., additional, Rhrissorrakrai, Kahn, additional, Utro, Filippo, additional, Levovitz, Chaya, additional, Denault, Elyssa, additional, Walmsley, Charlotte S., additional, Kambadakone, Avinash, additional, Stone, James R., additional, Isakoff, Steven J., additional, Parida, Laxmi, additional, Juric, Dejan, additional, Getz, Gad, additional, Bardia, Aditya, additional, and Ellisen, Leif W., additional

Published
2021
Full Text
View/download PDF

9. Abstract 37: Convergence of resistance patterns in breast cancer after multiple lines of treatment through analysis of rapid autopsy samples

Author

Leshchiner, Ignaty, primary, Martin, Elizabeth E., additional, Chen, Christopher T., additional, Leshchiner, Elizaveta, additional, Zhang, Thomas, additional, Pinto, Christopher, additional, Utro, Filippo, additional, Rhrissorrakrai, Kahn, additional, Levovitz, Chaya, additional, Danysh, Brian P., additional, Slowik, Kara, additional, Jacobs, Raquel A., additional, Parida, Laxmi, additional, Getz, Gad, additional, and Juric, Dejan, additional

Published
2021
Full Text
View/download PDF

10. Liquid versus tissue biopsy for detecting acquired resistance and tumor heterogeneity in gastrointestinal cancers

Author

Parikh, Aparna R., primary, Leshchiner, Ignaty, additional, Elagina, Liudmila, additional, Goyal, Lipika, additional, Levovitz, Chaya, additional, Siravegna, Giulia, additional, Livitz, Dimitri, additional, Rhrissorrakrai, Kahn, additional, Martin, Elizabeth E., additional, Van Seventer, Emily E., additional, Hanna, Megan, additional, Slowik, Kara, additional, Utro, Filippo, additional, Pinto, Christopher J., additional, Wong, Alicia, additional, Danysh, Brian P., additional, de la Cruz, Ferran Fece, additional, Fetter, Isobel J., additional, Nadres, Brandon, additional, Shahzade, Heather A., additional, Allen, Jill N., additional, Blaszkowsky, Lawrence S., additional, Clark, Jeffrey W., additional, Giantonio, Bruce, additional, Murphy, Janet E., additional, Nipp, Ryan D., additional, Roeland, Eric, additional, Ryan, David P., additional, Weekes, Colin D., additional, Kwak, Eunice L., additional, Faris, Jason E., additional, Wo, Jennifer Y., additional, Aguet, François, additional, Dey-Guha, Ipsita, additional, Hazar-Rethinam, Mehlika, additional, Dias-Santagata, Dora, additional, Ting, David T., additional, Zhu, Andrew X., additional, Hong, Theodore S., additional, Golub, Todd R., additional, Iafrate, A. John, additional, Adalsteinsson, Viktor A., additional, Bardelli, Alberto, additional, Parida, Laxmi, additional, Juric, Dejan, additional, Getz, Gad, additional, and Corcoran, Ryan B., additional

Published
2019
Full Text
View/download PDF

11. Renal Cell Carcinoma With TFEBTranslocation Versus Unclassified Renal Cell Carcinoma With TFEBAmplification

Author

Martin, Elizabeth E., Mehra, Rohit, Jackson-Cook, Colleen, and Smith, Steven Christopher

Abstract

Microphthalmia transcription factor (MiT)–family translocation renal cell carcinomas (RCCs) are an unusual but increasingly recognized group of RCC defined by recurrent gene rearrangements involving the TFE3or TFEBloci. These genes belong to the MiT family, imparting a unique expression of melanocytic markers seen in these tumors. The Xp11 translocation RCCs are more common and better studied than their t(6;11) translocation RCC counterpart, and the newly emerging entity of TFEB-amplified RCC (technically falling under the unclassified category of RCC) has emerged only as a few case reports and small series. Herein, we present 2 cases with careful workup, followed by a discussion of MiT family translocation RCC, particularly t(6;11) translocation RCC and TFEB-amplified RCC. We will emphasize the clinical and epidemiological features, including emerging potential prognostic differences, the gross and microscopic findings for the tumors, and the immunohistochemical and molecular findings to date, including changes at the TFEBlocus. We also discuss the differential diagnosis of these tumors with recommendations for prospective practice.

Published
2017
Full Text
View/download PDF

13. Allosteric PI3Kα Inhibition Overcomes On-target Resistance to Orthosteric Inhibitors Mediated by Secondary PIK3CA Mutations.

Author

Varkaris A, Fece de la Cruz F, Martin EE, Norden BL, Chevalier N, Kehlmann AM, Leshchiner I, Barnes H, Ehnstrom S, Stavridi AM, Yuan X, Kim JS, Ellis H, Papatheodoridi A, Gunaydin H, Danysh BP, Parida L, Sanidas I, Ji Y, Lau K, Wulf GM, Bardia A, Spring LM, Isakoff SJ, Lennerz JK, Del Vecchio K, Pierce L, Pazolli E, Getz G, Corcoran RB, and Juric D

Subjects
Humans, Female, Fulvestrant, Phosphoinositide-3 Kinase Inhibitors, Class I Phosphatidylinositol 3-Kinases genetics, Mutation, Phosphatidylinositol 3-Kinases genetics, Phosphatidylinositol 3-Kinases metabolism, Breast Neoplasms drug therapy, Breast Neoplasms genetics, Breast Neoplasms metabolism
Abstract

PIK3CA mutations occur in ∼8% of cancers, including ∼40% of HR-positive breast cancers, where the PI3K-alpha (PI3Kα)-selective inhibitor alpelisib is FDA approved in combination with fulvestrant. Although prior studies have identified resistance mechanisms, such as PTEN loss, clinically acquired resistance to PI3Kα inhibitors remains poorly understood. Through serial liquid biopsies and rapid autopsies in 39 patients with advanced breast cancer developing acquired resistance to PI3Kα inhibitors, we observe that 50% of patients acquire genomic alterations within the PI3K pathway, including PTEN loss and activating AKT1 mutations. Notably, although secondary PIK3CA mutations were previously reported to increase sensitivity to PI3Kα inhibitors, we identified emergent secondary resistance mutations in PIK3CA that alter the inhibitor binding pocket. Some mutations had differential effects on PI3Kα-selective versus pan-PI3K inhibitors, but resistance induced by all mutations could be overcome by the novel allosteric pan-mutant-selective PI3Kα-inhibitor RLY-2608. Together, these findings provide insights to guide strategies to overcome resistance in PIK3CA-mutated cancers., Significance: In one of the largest patient cohorts analyzed to date, this study defines the clinical landscape of acquired resistance to PI3Kα inhibitors. Genomic alterations within the PI3K pathway represent a major mode of resistance and identify a novel class of secondary PIK3CA resistance mutations that can be overcome by an allosteric PI3Kα inhibitor. See related commentary by Gong and Vanhaesebroeck, p. 204 . See related article by Varkaris et al., p. 240 . This article is featured in Selected Articles from This Issue, p. 201., (©2023 The Authors; Published by the American Association for Cancer Research.)

Published
2024
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results